ECSP055818A - Métodos y composiciones para inducir apoptosis en células de cáncer. - Google Patents
Métodos y composiciones para inducir apoptosis en células de cáncer.Info
- Publication number
- ECSP055818A ECSP055818A EC2005005818A ECSP055818A ECSP055818A EC SP055818 A ECSP055818 A EC SP055818A EC 2005005818 A EC2005005818 A EC 2005005818A EC SP055818 A ECSP055818 A EC SP055818A EC SP055818 A ECSP055818 A EC SP055818A
- Authority
- EC
- Ecuador
- Prior art keywords
- cancer cells
- compositions
- methods
- induce apoptosis
- apoptosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/207—Modifications characterised by siRNA, miRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Anticuerpos agonistas anti-DR4 o anti-DR5, combinados con agentes inductores de la apoptosis, inducen sigérgicamente apoptosis en células de cáncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42984202P | 2002-11-27 | 2002-11-27 | |
US44896003P | 2003-02-21 | 2003-02-21 | |
US49471403P | 2003-08-12 | 2003-08-12 | |
US50490103P | 2003-09-22 | 2003-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055818A true ECSP055818A (es) | 2006-01-27 |
Family
ID=32475709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005818A ECSP055818A (es) | 2002-11-27 | 2005-05-26 | Métodos y composiciones para inducir apoptosis en células de cáncer. |
Country Status (17)
Country | Link |
---|---|
US (2) | US7229617B2 (es) |
EP (1) | EP1576179B1 (es) |
JP (1) | JP2006514096A (es) |
KR (3) | KR20090046973A (es) |
AT (1) | ATE481092T1 (es) |
AU (1) | AU2003297579A1 (es) |
BR (1) | BR0316737A (es) |
CA (1) | CA2507077A1 (es) |
CO (1) | CO5640147A2 (es) |
DE (1) | DE60334247D1 (es) |
EC (1) | ECSP055818A (es) |
MX (1) | MXPA05005726A (es) |
NO (1) | NO20052922L (es) |
PL (1) | PL210174B1 (es) |
PT (1) | PT1576179E (es) |
RU (1) | RU2379056C2 (es) |
WO (1) | WO2004050895A2 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
US20060062786A1 (en) * | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US20050129616A1 (en) * | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US20050214209A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
US7361341B2 (en) * | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
US20030180296A1 (en) * | 2001-12-20 | 2003-09-25 | Theodora Salcedo | Antibodies that immunospecifically bind to trail receptors |
DE60334247D1 (de) * | 2002-11-27 | 2010-10-28 | Irm Llc | Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen |
CN1980957A (zh) | 2004-03-23 | 2007-06-13 | 比奥根艾迪克Ma公司 | 受体偶联剂及其治疗用途 |
US8440610B2 (en) | 2004-11-12 | 2013-05-14 | Massachusetts Institute Of Technology | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells |
US20060115453A1 (en) * | 2004-11-12 | 2006-06-01 | Yaffe Michael B | Methods and compositions for treating cellular proliferative diseases |
JP2008536820A (ja) * | 2005-03-24 | 2008-09-11 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 癌のdr5アゴニストに対するmyc依存性感受性の増強 |
US7772177B2 (en) * | 2005-05-18 | 2010-08-10 | Aegera Therapeutics, Inc. | BIR domain binding compounds |
US8029989B2 (en) * | 2005-08-26 | 2011-10-04 | The Trustees Of The University Of Pennsylvania | Method using snail transcriptional repressor |
CA2564872C (en) * | 2005-10-25 | 2010-12-21 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
ES2388932T3 (es) * | 2005-12-02 | 2012-10-19 | Genentech, Inc. | Polipéptidos de unión y usos de los mismos |
TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
GB0606096D0 (en) | 2006-03-27 | 2006-05-03 | Cbmm Sa | Screening method |
NZ572836A (en) * | 2006-05-16 | 2011-12-22 | Pharmascience Inc | Iap bir domain binding compounds |
TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法 |
WO2008066854A2 (en) * | 2006-11-28 | 2008-06-05 | Novartis Ag | Methods and compositions for inducing apoptosis in cancer cells |
US20100203012A1 (en) * | 2007-05-30 | 2010-08-12 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
WO2008154439A1 (en) * | 2007-06-08 | 2008-12-18 | Irm Llc | Methods and compositions for inducing apoptosis in cancer cells |
US20100183604A1 (en) * | 2007-06-19 | 2010-07-22 | Takeda Pharmaceutical Company Limited | Preventive/remedy for cancer |
US20100272706A1 (en) | 2007-06-22 | 2010-10-28 | Jason Mercer | Antivirals |
EP2399610A3 (en) | 2007-09-24 | 2012-09-05 | Bar-Ilan University | Polymer nanoparticles coated by magnetic metal oxide and uses thereof |
WO2009136290A1 (en) * | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
AU2009261919A1 (en) * | 2008-06-27 | 2009-12-30 | Pharmascience Inc. | Bridged secondary amines and use thereof as IAP BIR domain binding compounds |
WO2010033315A1 (en) * | 2008-09-22 | 2010-03-25 | Amgen Inc. | Method of treatment |
EP2379742A2 (en) * | 2008-12-18 | 2011-10-26 | Centre National de la Recherche Scientifique - CNRS | Method for identifying genes involved in trail-induced apoptosis and therapeutic applications thereof |
WO2011057099A2 (en) | 2009-11-05 | 2011-05-12 | The Uab Research Foundation | Treating basal-like genotype cancers |
US9238069B2 (en) | 2009-12-16 | 2016-01-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
SG182724A1 (en) | 2010-02-12 | 2012-08-30 | Pharmascience Inc | Iap bir domain binding compounds |
UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
US10016440B2 (en) | 2010-04-21 | 2018-07-10 | Ventirx Pharmaceuticals, Inc. | Methods of enhancing antibody-dependent cellular cytotoxicity |
JP5918143B2 (ja) | 2010-10-29 | 2016-05-18 | 第一三共株式会社 | 新規抗dr5抗体 |
US20130266590A1 (en) | 2010-12-13 | 2013-10-10 | Novartis Ag | Dimeric iap inhibitors |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
US20140187604A1 (en) * | 2011-05-03 | 2014-07-03 | Dana-Farber Cancer Institute, Inc. | Therapeutic and diagnostic target gene in acute myeloid leukemia |
RU2488408C1 (ru) * | 2012-03-22 | 2013-07-27 | государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) | Средство и способ индукции апоптоза опухолевых клеток |
UA118028C2 (uk) * | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
SG11201705116SA (en) | 2015-01-20 | 2017-08-30 | Igm Biosciences Inc | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
KR20170105622A (ko) | 2015-01-26 | 2017-09-19 | 마크로제닉스, 인크. | Dr5-결합 도메인을 포함하는 다가 분자 |
US10849912B2 (en) | 2016-02-09 | 2020-12-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment |
CN109810194B (zh) * | 2017-11-21 | 2020-11-03 | 深圳市中科艾深医药有限公司 | 抗dr5的抗体及其制备方法和应用 |
CN109810193B (zh) * | 2017-11-21 | 2020-11-03 | 深圳市中科艾深医药有限公司 | 抗dr5的抗体及其制备方法和应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
AU8081491A (en) | 1990-06-01 | 1991-12-31 | Cetus Corporation | Compositions and methods for identifying biologically active molecules |
CA2189634A1 (en) | 1994-05-06 | 1995-11-16 | John J. Baldwin | Combinatorial dihydrobenzopyran library |
US5663046A (en) | 1994-06-22 | 1997-09-02 | Pharmacopeia, Inc. | Synthesis of combinatorial libraries |
US6342369B1 (en) | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
AUPQ599500A0 (en) | 2000-03-02 | 2000-03-23 | Walter And Eliza Hall Institute Of Medical Research, The | Novel peptides, modulatory agents therefor and methods of using them |
US7279160B2 (en) * | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
TWI318983B (en) * | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
CA2420534A1 (en) | 2000-08-24 | 2002-02-28 | Thomas Jefferson University | An iap binding peptide or polypeptide and methods of using the same |
AU2002360307B2 (en) * | 2001-11-01 | 2008-01-17 | The Uab Research Foundation | Combinations of DR5 antibody and other therapeutic agents |
ES2357225T3 (es) * | 2001-11-01 | 2011-04-20 | Uab Research Foundation | Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos. |
DE60334247D1 (de) | 2002-11-27 | 2010-10-28 | Irm Llc | Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen |
WO2005114187A2 (en) | 2004-04-23 | 2005-12-01 | The United States Of America As Represented By Thesecretary, Department Of Health And Human Services | Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation |
JP2008504029A (ja) | 2004-06-21 | 2008-02-14 | ワシントン・ユニバーシティ | 西ナイルウイルスに対する抗体ならびにその治療的および予防的使用 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
-
2003
- 2003-11-25 DE DE60334247T patent/DE60334247D1/de not_active Expired - Lifetime
- 2003-11-25 EP EP03812460A patent/EP1576179B1/en not_active Expired - Lifetime
- 2003-11-25 CA CA002507077A patent/CA2507077A1/en not_active Abandoned
- 2003-11-25 JP JP2004570962A patent/JP2006514096A/ja active Pending
- 2003-11-25 KR KR1020097008490A patent/KR20090046973A/ko not_active Application Discontinuation
- 2003-11-25 PL PL377726A patent/PL210174B1/pl not_active IP Right Cessation
- 2003-11-25 RU RU2005120167/15A patent/RU2379056C2/ru not_active IP Right Cessation
- 2003-11-25 AU AU2003297579A patent/AU2003297579A1/en not_active Abandoned
- 2003-11-25 MX MXPA05005726A patent/MXPA05005726A/es active IP Right Grant
- 2003-11-25 BR BR0316737-2A patent/BR0316737A/pt not_active Application Discontinuation
- 2003-11-25 KR KR1020057009571A patent/KR100915257B1/ko not_active IP Right Cessation
- 2003-11-25 KR KR1020077028013A patent/KR20070122578A/ko not_active Application Discontinuation
- 2003-11-25 PT PT03812460T patent/PT1576179E/pt unknown
- 2003-11-25 AT AT03812460T patent/ATE481092T1/de active
- 2003-11-25 US US10/723,383 patent/US7229617B2/en not_active Expired - Fee Related
- 2003-11-25 WO PCT/US2003/037940 patent/WO2004050895A2/en active Search and Examination
-
2005
- 2005-05-26 EC EC2005005818A patent/ECSP055818A/es unknown
- 2005-06-15 NO NO20052922A patent/NO20052922L/no not_active Application Discontinuation
- 2005-06-27 CO CO05062795A patent/CO5640147A2/es not_active Application Discontinuation
-
2006
- 2006-12-01 US US11/607,208 patent/US8173128B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
RU2379056C2 (ru) | 2010-01-20 |
CA2507077A1 (en) | 2004-06-17 |
RU2005120167A (ru) | 2006-03-10 |
KR100915257B1 (ko) | 2009-09-03 |
WO2004050895A2 (en) | 2004-06-17 |
NO20052922D0 (no) | 2005-06-15 |
US7229617B2 (en) | 2007-06-12 |
CO5640147A2 (es) | 2006-05-31 |
KR20090046973A (ko) | 2009-05-11 |
AU2003297579A1 (en) | 2004-06-23 |
PT1576179E (pt) | 2010-12-21 |
WO2004050895A3 (en) | 2005-12-08 |
BR0316737A (pt) | 2005-12-13 |
KR20070122578A (ko) | 2007-12-31 |
EP1576179B1 (en) | 2010-09-15 |
JP2006514096A (ja) | 2006-04-27 |
ATE481092T1 (de) | 2010-10-15 |
US8173128B2 (en) | 2012-05-08 |
EP1576179A4 (en) | 2007-06-06 |
EP1576179A2 (en) | 2005-09-21 |
PL210174B1 (pl) | 2011-12-30 |
PL377726A1 (pl) | 2006-02-06 |
US20050079172A1 (en) | 2005-04-14 |
DE60334247D1 (de) | 2010-10-28 |
MXPA05005726A (es) | 2005-08-16 |
US20070128204A1 (en) | 2007-06-07 |
KR20050094811A (ko) | 2005-09-28 |
NO20052922L (no) | 2005-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055818A (es) | Métodos y composiciones para inducir apoptosis en células de cáncer. | |
HN2005029978A (es) | Formulaciones | |
CY1122522T1 (el) | Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος | |
AR048819A1 (es) | Metodos sinergicos y composiciones para el tratamiento del cancer | |
BRPI0511396A (pt) | derivados de retinal e métodos para uso no tratamento de enfermidades visuais | |
TW200501960A (en) | Synergistic kits and compositions for treating cancer | |
MY160041A (en) | Compositions and methods for treating parasitic infections | |
ECSP056132A (es) | Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis | |
UY30492A1 (es) | Anticuerpo antagonista para el tratamiento del cancer | |
MX2009006505A (es) | Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para usarlas en el tratamiento de la presbiopia. | |
ECSP067046A (es) | Indazoles sustituidos, composiciones que los contienen, procedimiento de preparación y su uso | |
AR060241A1 (es) | Composiciones y metodos de uso para anticuerpos de c-met | |
NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo | |
CL2008003122A1 (es) | Uso de un anticuerpo anti-cd20 de tipo ii util para preparar un medicamento para tratar un cancer que expresa cd20 en combinacion con un inhibidor de proteasoma, composicion farmaceutica que contiene dicha combinacion y kit del mismo | |
DE60028971D1 (de) | Apo-2l rezeptor-agonist und cpt-11 synergie-effekt | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
BRPI0909227A2 (pt) | uso de um anticorpo anti-cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não hodgkin. | |
WO2006137934A3 (en) | Purposeful movement of human migratory cells away from an agent source | |
CR9853A (es) | Compuestos de exemestano (s)-6-metiloxaalquilo y metodos relacionados con su utilizacion | |
HK1107778A1 (en) | Sodium stibogluconate and il-2 for treating cancer | |
WO2006075012A3 (en) | Pyrrolodihydroisoquinolines as antiproliferative agents | |
WO2007075706A3 (en) | Affinity optimized epha2 agonistic antibodies and methods of use thereof | |
RS52668B (en) | ANTITUMOR EFFECT, ANTI-TUMOR AND ANALYSIS PROCESS | |
WO2006002088A3 (en) | Amino-quinazoline derivatives as antitumor agents | |
AR051844A1 (es) | Uso de agonistas beta de estrogenos en desordenes o enfermedades cognitivas |